Tag Archives: PCRX

Pacira Pharmaceuticals (PCRX) Receives a Buy from Northland Securities

Northland Securities analyst Tim Chiang maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) today and set a price target of $50.00. The company’s shares closed last Thursday at $33.71. Chiang has an average return of 8.7% when

A Director at Pacira Pharmaceuticals is Exercising Options

Yesterday it was reported that a Director at Pacira Pharmaceuticals (PCRX – Research Report), Gary Pace, exercised options to buy 21,736 PCRX shares at $4.45 a share, for a total transaction value of $96.84K. This recent transaction increases Gary Pace’s

Stifel Nicolaus Reiterates Their Hold Rating on Pacira Pharmaceuticals (PCRX)

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Pacira Pharmaceuticals (PCRX – Research Report), with a price target of $49.00. The company’s shares closed last Monday at $49.19, close to its 52-week high

Monday’s Highlights at Noon: Second Sight Medical Products (EYES), Novavax (NVAX), Rite Aid (RAD), Arrowhead Research (ARWR), Pacira Pharmaceuticals (PCRX)

So far Monday, February 10, NASDAQ is up 2.58% and the S&P is up 1.86%. Here are this morning’s most active stocks: Second Sight Medical Products (EYES – Research Report), Novavax (NVAX – Research Report), Rite Aid (RAD – Research

Wedbush Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) today and set a price target of $85.00. The company’s shares closed last Monday at $42.75. According to TipRanks.com, Moussatos is a 1-star analyst with

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX) and Intercept Pharma (NASDAQ: ICPT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pacira Pharmaceuticals (PCRX – Research Report) and Intercept Pharma (ICPT – Research Report) with bullish sentiments. Pacira Pharmaceuticals (PCRX) RBC Capital analyst